Although it was initially illustrated that among all antidiabetic medications with effect on hypertension (DPP4 inhibitors, GLP-1RAs, and SGLT2-i), the most significant decrease was observed in patients treated with GLP-1 RAs [71], a recent meta-analysis indicated that SGLT2-i have a more considerable effect [72]. This evidence concerns the gene SLC5A2 and Hypertension.